Competitive Intelligence
Competitive Intelligence Briefing — Cosentyx
Week ending August 30, 2026
1. Competitive landscape snapshot
Eight competitors appeared in answers about Cosentyx. The leading set remains tightly grouped:
- Humira: 15 mentions
- Stelara: 14
- Enbrel: 14
- Taltz: 14
- Remicade: 6
- Skyrizi: 4
- Tremfya: 2
- Bimzelx: 1
The first four account for 57 of 80 total competitor mentions. Most of that visibility is tied to explicit comparison prompts: Humira, Stelara, and Taltz each have six responses to directly comparative questions; Enbrel appears in five of six responses to its explicit comparison question. The remaining mentions are largely incidental references in broader mechanism, dosing, switching, or interaction answers. Remicade, Skyrizi, Tremfya, and Bimzelx are primarily incidental rather than the subject of a head-to-head question.
2. How the comparison is currently framed
AI answers are predominantly neutral, balanced, and hedged, rather than consistently favoring Cosentyx or a competitor.
- Humira: The six direct comparisons frame both products as highly effective while emphasizing different mechanisms, response timing, and side-effect patterns. The recurring language is: “Both are effective for many people” and “individual responses vary.” This creates parity, not a clear Cosentyx advantage.
- Taltz: The comparison is explicitly framed around shared decision-making: “both are legitimate options,” “fit” rather than “winner/loser,” and avoiding claims that either drug is better. This is the clearest example of noncommittal positioning between close class competitors.
- Stelara: Answers distinguish IL-17A versus IL-12/23 targeting, dosing, and practical safety considerations, but do not establish a winner.
- Enbrel: Responses reject the patient question of whether Cosentyx is “stronger,” instead describing “different mechanism and comparable effectiveness.”
Superiority language is present but generally not asserted as an outcome. All six Taltz responses contain tagged terms such as “best,” “stronger,” or “superior,” yet the actual excerpts instruct users to avoid those rankings. Five Enbrel responses similarly contain “stronger” or “best” language while explicitly rejecting a stronger/weaker hierarchy. One Humira response includes “best,” but the surrounding framing remains balanced. No competitor is consistently portrayed as superior to Cosentyx.
3. Movers — who’s gaining or losing ground
Week over week:
- Gaining: Remicade +2 (4 to 6); Bimzelx +1 (0 to 1)
- Declining: Humira −3, Enbrel −3, Stelara −2, Taltz −2, Tremfya −1
- Absent this week: Rinvoq, down from 2 to 0
The Remicade increase is notable: it rose from 3 mentions on July 26 to 6 this week, after a dip to 2 on August 2. Bimzelx is a new re-entry versus last week, although it appeared in earlier weeks. Across the full period, Humira, Stelara, and Enbrel remain above their July baselines, while Taltz is slightly below its July level. The increase in cross-response inconsistency flags—from 26 to 29—also makes this week’s framing less uniform.
4. Questions worth watching
- Cosentyx versus Taltz: a high-volume, direct comparison with six responses and repeated “both are reasonable options” framing.
- Cosentyx versus Humira in plaque psoriasis: six responses focused on effectiveness timing and side-effect experience, without a clear winner.
- Cosentyx versus Stelara: six responses emphasizing mechanism, dosing, and practical differences; relevant to treatment-switch conversations.
- Whether Cosentyx is “stronger” than Enbrel: a notably one-sided prompt toward superiority, but answers consistently decline to rank the products.
5. Recommended actions
- Monitor Remicade next week to determine whether the +2 increase represents a sustained rise or question-mix noise.
- Track Bimzelx explicitly as a potential emerging IL-17 comparison, following its return to the conversation at one mention.
- Brief the brand/strategy team on parity framing: AI currently positions Cosentyx alongside major competitors rather than as a clear category winner.
- Review Taltz and Enbrel comparisons as competitive perception signals, particularly the repeated “stronger” prompt and the consistent rejection of a simple ranking.
- Continue routine monitoring of Humira, Stelara, Enbrel, and Taltz; their small weekly declines do not yet indicate a material competitive shift.